Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Chiasma Inc (CHMA)

Chiasma Inc (CHMA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 185,711
  • Shares Outstanding, K 42,016
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,260 K
  • 60-Month Beta 1.16
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.22
  • Number of Estimates 4
  • High Estimate -0.17
  • Low Estimate -0.28
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.12 +5.34%
on 02/27/20
5.07 -14.40%
on 02/04/20
-0.24 (-5.24%)
since 01/27/20
3-Month
4.12 +5.34%
on 02/27/20
5.65 -23.19%
on 12/24/19
-1.11 (-20.37%)
since 11/27/19
52-Week
4.12 +5.34%
on 02/27/20
9.25 -53.08%
on 07/23/19
+0.21 (+5.08%)
since 02/27/19

Most Recent Stories

More News
Neuroendocrine Carcinoma Market is projected to grow at a high 7.7% CAGR throughout 2017-2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions...

AMGN : 212.04 (-1.17%)
CELGZ : 0.47 (+2.15%)
CHMA : 4.45 (+0.68%)
HCM : 24.55 (+2.55%)
LXRX : 2.89 (+1.05%)
NVS : 88.33 (+1.40%)
TEVA : 12.86 (-1.23%)
VRX.TO : 30.80 (-3.33%)
Chiasma Announces FDA Acceptance of MYCAPSSA(R) New Drug Application Resubmission

FDA sets PDUFA date of June 26, 2020

CHMA : 4.45 (+0.68%)
Chiasma Provides Corporate Update and Previews 2020 Milestones

MYCAPSSA NDA resubmitted to FDA; PDUFA decision expected mid-2020

CHMA : 4.45 (+0.68%)
Chiasma Added to NASDAQ Biotechnology Index

Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has been selected for...

CHMA : 4.45 (+0.68%)
Neuroendocrine Carcinoma Market is Anticipated to Expand at a Healthy CAGR of 7.7% During the Forecast Period 2017 – 2027

Recently, Future Market Insights has presented value analysis and insights on the various disease types, treatment types and end users associated with the neuroendocrine carcinoma market across key regions...

AMGN : 212.04 (-1.17%)
CELGZ : 0.47 (+2.15%)
CHMA : 4.45 (+0.68%)
HCM : 24.55 (+2.55%)
LXRX : 2.89 (+1.05%)
NVS : 88.33 (+1.40%)
TEVA : 12.86 (-1.23%)
VRX.TO : 30.80 (-3.33%)
Chiasma to Present at the Piper Jaffray 31st Annual Healthcare Conference

Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive...

CHMA : 4.45 (+0.68%)
Chiasma to Present at the 13th Acromegaly Consensus Conference

Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that William Ludlam, M.D., Ph.D.,...

CHMA : 4.45 (+0.68%)
Chiasma: 3Q Earnings Snapshot

WALTHAM, Mass. (AP) _ Chiasma Inc. (CHMA) on Tuesday reported a loss of $7.7 million in its third quarter.

CHMA : 4.45 (+0.68%)
Chiasma Reports Third Quarter 2019 Results

CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints

CHMA : 4.45 (+0.68%)
Chiasma Supports Acromegaly Awareness Day

Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today recognizes November 1 as Acromegaly Awareness...

CHMA : 4.45 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade CHMA with:

Business Summary

Chiasma, Inc. is a biopharmaceutical company. The company's TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA.

See More

Key Turning Points

2nd Resistance Point 4.60
1st Resistance Point 4.51
Last Price 4.48
1st Support Level 4.36
2nd Support Level 4.30

See More

52-Week High 9.25
Fibonacci 61.8% 7.29
Fibonacci 50% 6.68
Fibonacci 38.2% 6.08
Last Price 4.48
52-Week Low 4.12

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar